TNFRSF18 anticorps (PerCP-Cy5.5)

N° du produit ABIN2660096

Détail du produit anti-TNFRSF18 anticorps (PerCP-Cy5.5)

Antigène: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF18 est conjugé à/à la PerCP-Cy5.5

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Clone: DTA-1

Isotype: IgG2b lambda

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TNFRSF18

Antigène: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Autre désignation: CD357 (TNFRSF18 Produits)

Synonymes: anticorps GITR, anticorps TNFRSF18, anticorps AITR, anticorps Gitr, anticorps CD357, anticorps GITR-D, anticorps TNF receptor superfamily member 18, anticorps tumor necrosis factor receptor superfamily, member 18, anticorps TNFRSF18, anticorps Tnfrsf18

Sujet: GITR (glucocorticoid-induced TNFR-related gene) is a member of the TNF receptor superfamily, also known as TNFRSF18 and AITR (in humans). It is expressed at low levels on resting T lymphocytes and at high levels on CD25+ CD4+ Tregs. The expression of GITR on T cells can be upregulated upon activation. Interaction of GITR with its ligand (GITRL) has been demonstrated to augment T cell activation, proliferation, cytokine production as well as MAPKs and NF-κB activation, and abrogate the inhibitory function of CD25+ CD4+ Tregs. In vivo activation of GITR causes development of autoimmune diseases and restores the suppressed immune response.

Pathways: Cancer Immune Checkpoints